Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 27, 2017

DrugPatentWatch Database Preview

Olmesartan medoxomil - Generic Drug Details

« Back to Dashboard

What are the generic sources for olmesartan medoxomil and what is the scope of freedom to operate?

Olmesartan medoxomil
is the generic ingredient in two branded drugs marketed by Mylan Pharms Inc and Daiichi Sankyo, and is included in two NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Olmesartan medoxomil has one hundred and twenty-nine patent family members in thirty-one countries.

There are thirty-five drug master file entries for olmesartan medoxomil. Twelve suppliers are listed for this compound. There are eighteen tentative approvals for this compound.

Summary for Generic Name: olmesartan medoxomil

Drug Master File Entries: see list35
Suppliers / Packagers: see list12
Bulk Api Vendors: see list81
Clinical Trials: see list44
Patent Applications: see list4,144
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:olmesartan medoxomil at DailyMed

Pharmacology for Ingredient: olmesartan medoxomil

Tentative approvals for OLMESARTAN MEDOXOMIL

Applicant Application No. Form Dosage
► Subscribe► SubscribeTABLET; ORAL5MG
► Subscribe► SubscribeTABLET; ORAL20MG
► Subscribe► SubscribeTABLET; ORAL40MG
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc
olmesartan medoxomil
TABLET;ORAL078276-001Oct 26, 2016ABRXNoNo► Subscribe► Subscribe
Daiichi Sankyo
olmesartan medoxomil
TABLET;ORAL021286-003Apr 25, 2002ABRXYesNo5,616,599*PED► Subscribe ► Subscribe
Daiichi Sankyo
olmesartan medoxomil
TABLET;ORAL021286-001Apr 25, 2002ABRXYesNo6,878,703*PED► SubscribeY► Subscribe
Daiichi Sankyo
olmesartan medoxomil
TABLET;ORAL021286-004Apr 25, 2002ABRXYesYes5,616,599*PED► Subscribe ► Subscribe
Mylan Pharms Inc
olmesartan medoxomil
TABLET;ORAL078276-002Oct 26, 2016ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Find generic sources and suppliers
  • Identify first generic entrants

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus